Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...

Medtronic reported late-breaking data on five-year outcomes from the Evolut Low Risk Trial. The Dublin-based company said data shows, vs. surgery, the Evolut transcatheter aortic valve replacement ...

Please provide your email address to receive an email when new articles are posted on . At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve replacement ...

WASHINGTON, DC — (Updated with commentary) The SURTAVI trial hit its noninferiority end point, making it the second prospective randomized trial to show transcatheter aortic-valve replacement (TAVR) ...

A new report is projecting that the transcatheter aortic valve replacement procedure will be the single-most dominant force driving the U.S. market for heart valves to more than $1.5 billion in 2016.

CHICAGO, IL — The largest-ever review of transcatheter aortic-valve replacement (TAVR) procedures for failed bioprosthetic valves suggests that TAVR could play a key role in solving a problem that ...

TCT 122: Perioperative and In-Hospital Outcomes of Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the National Inpatient Sample 2016-2021 Receive the ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...